Close Menu

NEW YORK — Centogene said on Thursday that it has priced its planned US initial public offering of 4 million shares at $14 apiece for total gross proceeds of roughly $56 million.

The company has also granted the underwriters of the offering a 30-day option to purchase an additional 600,000 shares at the offering price, which would add another $8.4 million to the IPO's value.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Dec
02
Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.